InflaRx Faces EMA Setback on GOHIBIC but Pivots to Izicopan for AAV in Europe

What happened

InflaRx announced it is assessing a broadened development and registrational strategy for ANCA-associated vasculitis (AAV) in Europe, following an EMA CHMP recommendation to revoke marketing authorization for Tavneos (vilobelimab/GOHIBIC) in the EU. This recommendation, while a clear negative for the legacy GOHIBIC asset, was largely anticipated given InflaRx's prior strategic pivot away from commercializing GOHIBIC. The company now appears to be accelerating its izicopan (oral C5aR inhibitor) program for AAV in Europe, potentially leveraging a differentiated regulatory pathway. However, the news introduces fresh uncertainty: the EMA's decision underscores the regulatory challenges facing C5a inhibition in AAV, and a broadened strategy for izicopan in Europe could increase R&D spending without a guaranteed faster path. The market's reaction will likely hinge on concrete details—trial design, timeline, and budget—expected at InflaRx's Capital Markets Day this summer.

Implication

For long-term investors, the EMA recommendation validates InflaRx's earlier decision to deprioritize GOHIBIC. The pivot to izicopan for AAV is logical but execution-dependent: the company must deliver a clear Phase 2 design, manage cash burn (already elevated after the May raise), and avoid overpromising. Success would transform IFRX into a pure-play oral C5aR developer with multiple shots on goal. Failure to execute would exacerbate dilution risk. Monitor Capital Markets Day for specifics.

Thesis delta

The EMA's negative action on GOHIBIC removes a residual commercial optionality but reinforces the urgency of izicopan's success. InflaRx's broadened AAV strategy in Europe shifts the focus from a single-asset salvage story to a multi-indication pipeline bet. This increases both upside potential (if izicopan differentiates) and risk (if burn accelerates without clear regulatory alignment). The WAIT rating remains until concrete AAV trial details and budget reconciliation are provided.